Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of MM09 sublingual spray for dust mite allergic rhinitis/rhinoconjunctivitis with or without mild to moderate controlled asthma
CTR20250787Phase 3Active
- Sponsor
- Inmunotek
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Clustoid MM09 in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by Inmunotek. Started Aug 2025; status: active.
02
Drugs
Clustoid MM09
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on CTR20250787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250787.